MarketCapExport financials
BioLife Solutions (BLFS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
BioLife Solutions Income Statement 2025-2009 | BLFS
Brief overview of profit and loss at BioLife Solutions
The figures are compared over a five-year interval. According to figures from BioLife Solutions, revenue changed from $48.1 million to $96.2 million over five years. The cumulative result was +100.1%, corresponding to roughly 14.9% per year. Top-line growth remained consistently strong over the period.
The operating result measured by EBITDA moved from −$4.2 million to −$14.3 million, or −241.2%. EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from −8.7% to −14.9%. Cost pressure reduced operating profitability.
Across the five years, the net result shifted from $2 million to −$4.6 million. Profit turned into a loss, the most concerning signal in the results.
Market value was 1 billion dollars at the start and 988 million dollars at the end. Market value lagged the financial performance.
Financial takeaway
The indicators point to a weaker financial profile. The financial profile benefits from revenue expansion. The most visible risks are weaker operating efficiency, limited operating profitability and a weaker final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement BioLife Solutions
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
988 M | 1.14 B | 738 M | 938 M | 1.15 B | 1.04 B | 285 M | 213 M | 72 M | 22.8 M | 21 M | 18.5 M | 39.5 M | 17.4 M | 4.18 M | 58.5 M | - |
Shares |
47.8 M | 46.1 M | 43.7 M | 42.5 M | 38.5 M | 27.3 M | 19.5 M | 16.3 M | 13.3 M | 12.6 M | 10.4 M | 10.4 M | 5.01 M | 4.98 M | 4.98 M | 69.7 M | - |
Historical Prices |
20.7 | 24.7 | 16.9 | 22.1 | 29.8 | 37.9 | 13.8 | 14.7 | 5.42 | 1.85 | 1.99 | 1.77 | 7.2 | 3.92 | 0.98 | 0.84 | 1.68 |
Net Income |
-4.6 M | -20.2 M | -68 M | -140 M | -8.91 M | 1.98 M | -1.66 M | 3.27 M | -2.52 M | -6.88 M | -3.3 B | -3.22 M | -1.08 M | -1.66 M | -1.96 M | -1.98 M | - |
Revenue |
96.2 M | 74.6 M | 68 M | 76.2 M | 119 M | 48.1 M | 27.4 M | 19.7 M | 11 M | 8.23 M | 6.19 B | 6.19 M | 8.95 M | 5.66 M | 2.76 M | - | - |
Cost of Revenue |
34.1 M | 24.6 M | 26.7 M | - | - | - | 8.76 M | 6.22 M | 4.28 M | 3.45 M | 2.63 M | 3.16 M | 5.19 M | 3.37 M | 1.36 M | 1.23 M | - |
Gross Profit |
62.1 M | 50.1 M | 41.3 M | - | - | - | 18.6 M | 13.5 M | 6.75 M | 4.78 M | 3.04 B | 3.04 M | 3.76 M | 2.29 M | 1.4 M | 856 K | - |
Operating Income |
-16.6 M | -4.48 M | -17.2 M | -5.92 M | -35.2 M | -6.24 M | -220 K | 3.66 M | -1.06 M | -4.85 M | -5.02 M | -3.14 M | -285 K | -942 K | -1.21 M | -1.39 M | - |
Interest Expense |
1.82 M | 494 K | 1.28 M | 662 K | 289 K | - | 5 K | 5 K | 190 K | 100 K | - | 177 K | 742 K | 733 K | 671 K | 588 K | - |
EBITDA |
-14.3 M | 683 K | -10.1 M | 852 K | -30.5 M | -4.21 M | 1.85 M | 4 M | -717 K | -4.48 M | -3.04 B | -2.88 M | -38.3 K | -773 K | -1.11 M | -1.32 M | - |
Operating Expenses |
- | - | - | - | - | - | 17.8 M | 9.86 M | 7.8 M | 9.63 M | 6.17 B | 6.17 M | 4.05 M | 3.23 M | 2.61 M | 2.25 M | - |
General and Administrative Expenses |
45.5 M | 40.6 M | 42.8 M | 33.3 M | 33.7 M | 15.3 M | 8.89 M | 5.95 M | 4.52 M | 4.59 M | 2.64 B | 3.97 M | 2.72 M | 2.15 M | 1.83 M | 1.5 M | - |
All numbers in USD currency
Quarterly Income Statement BioLife Solutions
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
48.9 M | 48.5 M | 47.9 M | 47.8 M | 47.1 M | 46.9 M | 46.2 M | 46 M | 45.4 M | 45.2 M | 43.6 M | 43.4 M | 43 M | 42.8 M | 42.6 M | 42.5 M | 42 M | 41.8 M | 40.9 M | 38.1 M | 33.2 M | 33 M | 31.6 M | 23.3 M | 21 M | 20.8 M | 19.7 M | 18.8 M | 18.6 M | 18.5 M | 17.3 M | 15.2 M | 14.1 M | 14 M | 13.2 M | 13.1 M | 13 M | 12.9 M | 12.7 M | 12.6 M | 12.5 M | 12.4 M | 12.2 M | 12.1 M | 12.1 M | 12.1 M | 12 M | 12 M | 5.57 M | 5.03 M | 5.01 M | 5 M | 4.99 M | 4.98 M | 69.7 M | 69.7 M | 69.7 M | 69.7 M | 69.7 M | 69.7 M | 69.7 M |
Net Income |
45.1 M | 1.19 M | 621 K | -15.8 M | -448 K | - | -1.7 M | -20.7 M | -10.2 M | - | -29.1 M | -10.2 M | -13.7 M | - | -10.3 M | -72.9 M | -7.42 M | - | 79 K | 7.88 M | -1.12 M | - | -1.13 M | -16.4 M | 22.3 M | - | 10.3 M | 4.25 M | -19.2 M | - | -24.5 M | -26.3 M | 4.87 M | - | -319 K | -768 K | -870 K | - | -969 K | -1.36 M | -1.23 M | - | -1.07 M | -994 K | -1.03 M | - | -862 K | -883 K | -559 K | - | -310 K | -283 K | -7.18 K | - | -352 K | -499 K | -297 K | - | -479 K | -437 K | -630 K |
Revenue |
28.5 M | 27.5 M | 28.1 M | 25.4 M | 23.9 M | - | 21.4 M | 19.7 M | 18.4 M | - | 23.6 M | 29.2 M | 37.7 M | - | 40.7 M | 40.5 M | 36.2 M | - | 33.8 M | 31.2 M | 16.8 M | - | 11.3 M | 9.92 M | 12.2 M | - | -291 K | -217 K | -232 K | - | -43 K | -177 K | -144 K | - | -218 K | -260 K | -229 K | - | - | - | - | - | 4.73 K | 5.48 K | 8.24 K | - | 7.66 K | 4.52 K | - | - | - | - | 2.16 M | - | 1.68 M | 1.1 M | 836 K | - | 716 K | 623 K | 611 K |
Cost of Revenue |
10.2 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.83 M | 4.5 M | 4.57 M | - | 2.09 M | 1.97 M | 1.65 M | - | 1.61 M | 1.54 M | 1.36 M | - | 1.1 M | 957 K | 928 K | - | 921 K | 873 K | 771 K | - | 659 K | 678 K | 618 K | - | 655 K | 667 K | 1.16 M | - | 1.28 M | 1.5 M | 1.03 M | - | 1.09 M | 642 K | 346 K | - | 346 K | 289 K | 369 K |
Gross Profit |
18.3 M | 17.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.52 M | 4.74 M | 4.12 M | - | 3.69 M | 3.64 M | 2.45 M | - | 1.87 M | 1.6 M | 1.44 M | - | 1.21 M | 1.12 M | 1.08 M | - | 973 K | 819 K | 883 K | - | 588 K | 545 K | 903 K | - | 889 K | 828 K | 1.13 M | - | 595 K | 456 K | 490 K | - | 370 K | 334 K | 242 K |
Operating Income |
1.7 M | 27 K | -89 K | -16.6 M | -1.22 M | - | -418 K | -1.31 M | -3.3 M | - | -15.5 M | -10.6 M | -13.6 M | - | -11.7 M | -76.6 M | -7.97 M | - | -11.2 M | -4.56 M | -981 K | - | -1.25 M | 44 K | 370 K | - | -772 K | 747 K | 566 K | - | 1.2 M | 1.28 M | 140 K | - | -32.3 K | -341 K | -464 K | - | -1.14 M | -1.59 M | -1.49 M | - | -1.3 M | -1.16 M | -1.16 M | - | -875 K | -888 K | -369 K | - | -110 K | -82.8 K | 192 K | - | -149 K | -307 K | -179 K | - | -285 K | -260 K | -454 K |
Interest Expense |
63 K | 180 K | 284 K | 247 K | 103 K | - | 97 K | 146 K | 253 K | - | 235 K | 384 K | 394 K | - | 142 K | -22 K | 131 K | - | -7 K | - | - | - | 3 K | - | 1 K | - | 1 K | 1 K | 3 K | - | 1 K | 1 K | 1 K | - | 1.08 K | 105 K | 83.3 K | - | 33.3 K | - | - | - | - | - | - | - | - | - | 177 K | - | 186 K | 186 K | 186 K | - | 186 K | 184 K | 179 K | - | 172 K | 165 K | 161 K |
EBITDA |
2.48 M | 401 K | 111 K | -16.4 M | -536 K | - | -218 K | -1.11 M | -1.93 M | - | -14.5 M | -9.83 M | -11.9 M | - | -10.8 M | -75.9 M | -6.31 M | - | -8.12 M | -2.66 M | -204 K | - | 208 K | 1.02 M | 783 K | - | -399 K | 956 K | 664 K | - | 1.44 M | 1.45 M | 218 K | - | 228 K | -165 K | -374 K | - | -862 K | -1.41 M | -1.4 M | - | -1.04 M | -987 K | -1.08 M | - | -688 K | -765 K | -307 K | - | 73.2 K | 35.4 K | 251 K | - | -38.7 K | -247 K | -153 K | - | -214 K | -214 K | -431 K |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.38 M | 5.95 M | 5.2 M | - | 2.49 M | 2.36 M | 2.31 M | - | 1.9 M | 1.94 M | 1.9 M | - | 2.35 M | 2.71 M | 2.57 M | - | 2.27 M | 1.97 M | 2.04 M | - | 1.46 M | 1.43 M | 1.27 M | - | 999 K | 911 K | 933 K | - | 744 K | 762 K | 669 K | - | 655 K | 594 K | 696 K |
General and Administrative Expenses |
10.7 M | 12.2 M | 12.1 M | 11.4 M | 11.5 M | - | 9.33 M | 9.32 M | 10.4 M | - | 10.8 M | 13.5 M | 14.8 M | - | 11.9 M | 11.7 M | 11.5 M | - | 10.1 M | 7.15 M | 4.83 M | - | 3.5 M | 3.28 M | 3.14 M | - | 2.35 M | 2.21 M | 2.15 M | - | 1.46 M | 1.39 M | 1.35 M | - | 1.12 M | 1.08 M | 1.1 M | - | 1.04 M | 1.26 M | 1.34 M | - | 1.26 M | 1.03 M | 1.22 M | - | 1.01 M | 970 K | 864 K | - | 630 K | 602 K | 624 K | - | 488 K | 475 K | 479 K | - | 500 K | 401 K | 454 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company BioLife Solutions (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 106.82 | 0.01 % | $ 5.04 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 111.75 | 1.1 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Nephros
NEPH
|
$ 4.29 | 2.88 % | $ 45.5 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.99 | 8.13 % | $ 293 M | USA |
 |
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | USA |
 |
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | USA |
 |
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | USA |
 |
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |